antipsychotic agents

Summary

Summary: Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in schizophrenia, senile dementia, transient psychosis following surgery or myocardial infarction, etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Top Publications

  1. ncbi Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
    Shitij Kapur
    Clarke Division of the Centre for Addiction and Mental Health, 250 College St, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 160:13-23. 2003
  2. ncbi A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?
    Sukanta Saha
    Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol Q4076, Australia
    Arch Gen Psychiatry 64:1123-31. 2007
  3. ncbi Chlorpromazine equivalent doses for the newer atypical antipsychotics
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    J Clin Psychiatry 64:663-7. 2003
  4. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
  5. pmc Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia
    Beng Choon Ho
    Departments of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
    Arch Gen Psychiatry 68:128-37. 2011
  6. ncbi Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
    Lancet 373:31-41. 2009
  7. ncbi Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia
    Effat S Emamian
    The Rockefeller University, Laboratory of Human Neurogenetics, 1230 York Avenue, Box 313, New York, New York 10021, USA
    Nat Genet 36:131-7. 2004
  8. ncbi Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database
    David P J Osborn
    Department of Mental Health Sciences, Royal Free Medical School, London, England
    Arch Gen Psychiatry 64:242-9. 2007
  9. ncbi Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Munich, Germany
    Lancet 379:2063-71. 2012
  10. ncbi Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design
    Roberto Coccurello
    Institute of Neuroscience, National Research Council C N R, Via del Fosso di Fiorano, 64 00143 Roma, Italy
    Pharmacol Ther 127:210-51. 2010

Research Grants

Detail Information

Publications377 found, 100 shown here

  1. ncbi Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
    Shitij Kapur
    Clarke Division of the Centre for Addiction and Mental Health, 250 College St, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 160:13-23. 2003
    ..The objective of this overview is to link the neurobiology (brain), the phenomenological experience (mind), and pharmacological aspects of psychosis-in-schizophrenia into a unitary framework...
  2. ncbi A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?
    Sukanta Saha
    Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol Q4076, Australia
    Arch Gen Psychiatry 64:1123-31. 2007
    ..Despite improvements in mental health services in recent decades, it is unclear whether the risk of mortality in schizophrenia has changed over time...
  3. ncbi Chlorpromazine equivalent doses for the newer atypical antipsychotics
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    J Clin Psychiatry 64:663-7. 2003
    ..Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed...
  4. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  5. pmc Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia
    Beng Choon Ho
    Departments of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
    Arch Gen Psychiatry 68:128-37. 2011
    ..Because antipsychotics are prescribed for long periods for schizophrenia patients and have increasingly widespread use in other psychiatric disorders, it is imperative to determine their long-term effects on the human brain...
  6. ncbi Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
    Lancet 373:31-41. 2009
    ....
  7. ncbi Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia
    Effat S Emamian
    The Rockefeller University, Laboratory of Human Neurogenetics, 1230 York Avenue, Box 313, New York, New York 10021, USA
    Nat Genet 36:131-7. 2004
    ....
  8. ncbi Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database
    David P J Osborn
    Department of Mental Health Sciences, Royal Free Medical School, London, England
    Arch Gen Psychiatry 64:242-9. 2007
    ..People with severe mental illness (SMI) appear to have an elevated risk of death from cardiovascular disease, but results regarding cancer mortality are conflicting...
  9. ncbi Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Munich, Germany
    Lancet 379:2063-71. 2012
    ..We aimed to assess the association between such drugs and various outcomes in patients with schizophrenia to resolve controversial issues...
  10. ncbi Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design
    Roberto Coccurello
    Institute of Neuroscience, National Research Council C N R, Via del Fosso di Fiorano, 64 00143 Roma, Italy
    Pharmacol Ther 127:210-51. 2010
    ..For this reason, recently identified obesogenic and diabetogenic mechanisms are the background on which the present work is built and some novel forthcoming lines of investigation suggested...
  11. ncbi Schizophrenia
    Kim T Mueser
    New Hampshire Dartmouth Psychiatric Research Center, Department of Psychiatry, Dartmouth
    Lancet 363:2063-72. 2004
    ....
  12. ncbi Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
    Sandeep T Patil
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Nat Med 13:1102-7. 2007
    ..These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia...
  13. ncbi Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    CNS Drugs 19:1-93. 2005
    ..trials indicates that weight gain liability varies significantly across the different second generation antipsychotic agents. Clozapine and olanzapine treatment are associated with the greatest risk of clinically significant weight ..
  14. pmc Increasing off-label use of antipsychotic medications in the United States, 1995-2008
    G C Alexander
    Department of Medicine, University of Chicago Hospitals, Chicago, Illinois, USA
    Pharmacoepidemiol Drug Saf 20:177-84. 2011
    ..We also quantified use without U.S. Food and Drug Administration approval (off-label use) and off-label use with compendium data suggesting an uncertain evidence base...
  15. pmc Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis
    Christine Rummel-Kluge
    Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Klinikum rechts der Isar, Möhlstr 26, 81675 Munchen, Germany
    Schizophr Res 123:225-33. 2010
    ..We conducted a meta-analysis of studies comparing the metabolic side effects of the following SGAs head-to-head: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine...
  16. pmc The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 36:71-93. 2010
    ....
  17. ncbi Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Mol Psychiatry 13:27-35. 2008
    ....
  18. pmc Genomewide association study of movement-related adverse antipsychotic effects
    Karolina Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Biol Psychiatry 67:279-82. 2010
    ..Understanding individual differences in the development of extrapyramidal side effects (EPS) as a response to antipsychotic therapy is essential to individualize treatment...
  19. ncbi The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?
    Chao Deng
    Centre for Translational Neuroscience, School of Health Sciences, University of Wollongong, Wollongong, 2522, NSW, Australia
    Prog Neuropsychopharmacol Biol Psychiatry 34:1-4. 2010
    ..In addition, atypical antipsychotics may affect food intake by influencing 5-HT, NA and ACh release via interactions with the H3 heteroreceptor...
  20. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  21. pmc Atypical antipsychotic drugs and the risk of sudden cardiac death
    Wayne A Ray
    Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville 37212, USA
    N Engl J Med 360:225-35. 2009
    ..However, less is known regarding the cardiac safety of the atypical antipsychotic drugs, which have largely replaced the older agents in clinical practice...
  22. ncbi What does the PANSS mean?
    Stefan Leucht
    Klinik für Psychiatrie und Psychotherapie der TU München Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 79:231-8. 2005
    ..g. at least 20% or 50% reduction of the baseline score) are as yet unclear. We therefore compared the PANSS with simultaneous ratings of Clinical Global Impressions (CGI)...
  23. ncbi H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs
    Wesley K Kroeze
    Department of Biochemistry, RM W463, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4935, USA
    Neuropsychopharmacology 28:519-26. 2003
    ....
  24. pmc Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs
    Nancy C Andreasen
    Mental Health Clinical Research Center, Department of Psychiatry, Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1057, USA
    Biol Psychiatry 67:255-62. 2010
    ..An expert consensus group has published charts of equivalent doses for various antipsychotic medications for first- and second-generation medications. These charts were used in this study...
  25. ncbi Trends in antipsychotic use in dementia 1999-2007
    Helen C Kales
    Veterans Affairs Health Services Researchand Development Center for Clinical Management Research, Serious Mental Illness Treatment, Resource, and Evaluation Center, Ann Arbor, Michigan, USA
    Arch Gen Psychiatry 68:190-7. 2011
    ..Concerns about their use began to emerge in 2002, and in 2005, the US Food and Drug Administration warned that use of atypical antipsychotics in dementia was associated with increased mortality...
  26. ncbi BDNF in schizophrenia, depression and corresponding animal models
    F Angelucci
    Institute of Neurology, Catholic University, Largo Gemelli, Rome, Italy
    Mol Psychiatry 10:345-52. 2005
    ..In this review, we summarize findings regarding altered BDNF in schizophrenia and depression and animal models, as well as the effects of antipsychotic and antidepressive treatments on the expression of BDNF...
  27. ncbi Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis
    Marc De Hert
    University Psychiatric Centre, Catholic University Leuven, Kortenberg, Belgium
    CNS Drugs 26:733-59. 2012
    ..However, until now, the metabolic risk profile of the newly approved SGAs - asenapine, iloperidone, lurasidone and paliperidone (paliperidone extended release and paliperidone palmitate) - has not been compared...
  28. ncbi Antipsychotic polypharmacy in schizophrenia: benefits and risks
    Thomas R E Barnes
    Division of Experimental Medicine, Centre for Mental Health, Imperial College London, Charing Cross Campus, London, UK
    CNS Drugs 25:383-99. 2011
    ..Further, their prescription for each patient should be in the context of an individual trial, with monitoring of the clinical response and adverse effects, and appropriate physical health monitoring...
  29. ncbi Risperidone in children with autism and serious behavioral problems
    James T McCracken
    University of California, Los Angeles, USA
    N Engl J Med 347:314-21. 2002
    Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with ..
  30. pmc Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs
    Miguel Fribourg
    Department of Structural and Chemical Biology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cell 147:1011-23. 2011
    ..These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia...
  31. ncbi Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review
    Max Marshall
    Division of Psychiatry, University of Manchester, Manchester
    Arch Gen Psychiatry 62:975-83. 2005
    ..It has been postulated that a longer DUP leads to a poorer prognosis. If so, outcome might be improved through earlier detection and treatment...
  32. ncbi Cytokines in schizophrenia and the effects of antipsychotic drugs
    Lukasz Drzyzga
    Silesian University School of Medicine, Department of Clinical Pharmacology, Medykow 18, 40 752 Katowice, Poland
    Brain Behav Immun 20:532-45. 2006
    ..Finally, limitations of the presented studies and prospects of future research are delineated...
  33. pmc Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys
    Glenn T Konopaske
    Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Biol Psychiatry 63:759-65. 2008
    ..Consequently, in this study we sought to determine whether the lower glial cell number was due to fewer oligodendrocytes as opposed to lower numbers of astrocytes...
  34. ncbi Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms
    Gavin P Reynolds
    Department of Psychiatry, Queen s University Belfast, Belfast BT9 7BL, UK
    Pharmacol Ther 125:169-79. 2010
    ..Understanding the pharmacology of metabolic consequences of current antipsychotic drug treatment is clearly the key to developing improved pharmacotherapies that avoid these problematic and limiting adverse effects...
  35. ncbi Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, Box 0984 F, San Francisco, CA 94143, USA
    Am J Psychiatry 166:980-91. 2009
    The authors sought to determine by meta-analysis the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder.
  36. ncbi Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005
    ..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia...
  37. ncbi Antipsychotic-induced weight gain: a comprehensive research synthesis
    D B Allison
    Obesity Research Center, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, NY 10025, UDA
    Am J Psychiatry 156:1686-96. 1999
    ..The purpose of this study was to estimate and compare the effects of antipsychotics-both the newer ones and the conventional ones-on body weight...
  38. ncbi The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
    Schizophr Res 68:283-97. 2004
    ..76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement...
  39. ncbi Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
    S Miyamoto
    Department of Neuropsychiatry, St Marianna University School of Medicine, Kawasaki, Japan
    Mol Psychiatry 10:79-104. 2005
    ....
  40. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada
    Bipolar Disord 11:225-55. 2009
    ..Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients' lives. This update provides an expanded look at bipolar II disorder...
  41. ncbi Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system
    Joanne Y T Leung
    Department of Pharmacology, University of British Columbia, 2176 Health Sciences Mall, Vancouver, B C V6T1Z3, Canada
    Pharmacol Ther 135:113-22. 2012
    ..The direct and indirect effects of antipsychotic drugs on the cardiovascular system and their possible mechanisms of action are discussed in this review, where both preclinical and clinical findings are integrated...
  42. ncbi Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
    D Robinson
    Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 56:241-7. 1999
    ..We examined relapse after response to a first episode of schizophrenia or schizoaffective disorder...
  43. ncbi A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry 25 Staniford Street, Boston, MA 02114, USA
    Schizophr Res 80:45-53. 2005
    ..The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics...
  44. pmc Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes
    Krista F Huybrechts
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
    CMAJ 183:E411-9. 2011
    ..We assessed the comparative safety of different classes of psychotropic medications used in nursing home residents...
  45. ncbi International consensus study of antipsychotic dosing
    David M Gardner
    Department of Psychiatry, Dalhousie University, Canada
    Am J Psychiatry 167:686-93. 2010
    ..Potency equivalents for anti-psychotic drugs are required to guide clinical dosing and for designing and interpreting research studies. Available dosing guidelines are limited by the methods and data from which they were generated...
  46. ncbi Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial
    Joo Cheol Shim
    Clinical Trial Center, Department of Psychiatry and Clinical Pharmacology, Busan Paik Hospital, Inje University, Busan 614 735, Republic of Korea
    Am J Psychiatry 164:1404-10. 2007
    ..The authors investigated the effect of adjunctive treatment with aripiprazole on hyperprolactinemia and psychopathology in patients with schizophrenia maintained with haloperidol...
  47. ncbi Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents
    Christoph U Correll
    The Zucker Hillside Hospital, Psychiatry Research, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    J Am Acad Child Adolesc Psychiatry 45:771-91. 2006
    ..Endocrine and metabolic adverse effects are among the most concerning adverse effects of commonly used psychotropic medications...
  48. ncbi Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity
    Tadashi Ishibashi
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Suita, Osaka, Japan
    J Pharmacol Exp Ther 334:171-81. 2010
    ..These results demonstrate that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects...
  49. pmc Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
    Christoph U Correll
    Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, 75 59 263rd St, Glen Oaks, NY 11004, USA
    JAMA 302:1765-73. 2009
    ..Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication...
  50. ncbi Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy
    Shitij Kapur
    Centre for Addiction and Mental Health, Clarke Site 250 College Street Toronto, Ontario Canada M5R 1T8
    J Pharmacol Exp Ther 305:625-31. 2003
    ..The study provides a rationale as well as clinically comparable dosing regimens for animal studies and raises questions about the inferences drawn from previous studies that have used doses unrepresentative of the clinical situation...
  51. ncbi Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Terry E Goldberg
    Zucker Hillside Hospital, 7559 263rd Street, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 64:1115-22. 2007
    ..However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects...
  52. ncbi Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
    T A P Lett
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Mol Psychiatry 17:242-66. 2012
    ..More research is required before genetically informed, personalized medicine can be applied to antipsychotic treatment; nevertheless, inroads have been made towards assessing genetic liability and plausible clinical application...
  53. pmc Reward processing in schizophrenia: a deficit in the representation of value
    James M Gold
    Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Schizophr Bull 34:835-47. 2008
    ..In contrast, patients often (but not always) approach normal performance levels on the slow learning achieved by the integration of reinforcement signals over many trials, thought to be mediated by the basal ganglia...
  54. ncbi A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychopharmacol 31:349-55. 2011
    ..Additional efficacy, safety, and tolerability testing are needed...
  55. ncbi Tardive dyskinesia and new antipsychotics
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Curr Opin Psychiatry 21:151-6. 2008
    ..To provide an update on tardive dyskinesia rates in patients treated with first-generation or second-generation antipsychotics in studies published since the last systematic review in 2004...
  56. ncbi Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
    Bryan L Roth
    Department of Biochemistry, School of Medicine, Case Western Reserve University, 2109 Adelbert Road, Cleveland, Ohio 44106, USA
    Nat Rev Drug Discov 3:353-9. 2004
  57. ncbi A systematic review of the effects of antipsychotic drugs on brain volume
    J Moncrieff
    Department of Mental Health Sciences, University College London, UK
    Psychol Med 40:1409-22. 2010
    ..People with schizophrenia are often found to have smaller brains and larger brain ventricles than normal, but the role of antipsychotic medication remains unclear...
  58. ncbi Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
    Marc De Hert
    University Psychiatric Center, Catholic University Leuven, Leuvensesteenweg 517, 3070 Kortenberg, Belgium marc de hert uc kortenberg be
    Nat Rev Endocrinol 8:114-26. 2012
    ..b>Antipsychotic agents with prominent metabolic adverse effects might cause abnormalities in glucose and lipid metabolism via both ..
  59. ncbi Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA
    JAMA 294:1934-43. 2005
    ....
  60. ncbi Antipsychotic medications: metabolic and cardiovascular risk
    John W Newcomer
    Department of Psychiatry, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:8-13. 2007
    ..Various strategies for monitoring cardiometabolic risk factors in patients with mental illness are discussed in this review...
  61. ncbi Long-acting risperidone and oral antipsychotics in unstable schizophrenia
    Robert A Rosenheck
    Veterans Affairs VA New England Mental Illness, Research Education and Clinical Center, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    N Engl J Med 364:842-51. 2011
    ....
  62. ncbi Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat
    G C Smith
    Department of Molecular Medicine and Pathology and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Diabetologia 51:2309-17. 2008
    ..We hypothesised that, in addition to the insulin resistance associated with the obesity, the SGAs might have acute effects on glucose metabolism that could contribute to the derangements in glucose metabolism...
  63. ncbi Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence
    Corrado Barbui
    Section of Psychiatry and Clinical Psychology, Department of Medicine and Public Health, University of Verona, Verona, Italy
    Psychopathology 42:311-7. 2009
    ..Factors influencing patient and clinician perspectives in the assessment of medication adherence have never been compared...
  64. ncbi GABA-based therapeutic approaches: GABAA receptor subtype functions
    Uwe Rudolph
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland, and Laboratory of Genetic Neuropharmacology, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Curr Opin Pharmacol 6:18-23. 2006
    ..Thus, a new pharmacology based on GABAA receptor subtype-specific actions is emerging...
  65. ncbi Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  66. pmc Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
    ....
  67. ncbi Metabolomic mapping of atypical antipsychotic effects in schizophrenia
    R Kaddurah-Daouk
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Mol Psychiatry 12:934-45. 2007
    ..A more definitive long-term randomized study of these drugs correlating global lipid changes with clinical outcomes could yield biomarkers that define drug-response phenotypes...
  68. ncbi Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia
    Diego Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Psychiatry Res 176:109-13. 2010
    ..Also, reversal of some risk factors may improve adherence. Non-adherence is associated with a range of poorer long-term outcomes, with clinical and economic implications...
  69. ncbi Predictors of noncompliance in patients with schizophrenia
    Diana O Perkins
    University of North Carolina Chapel Hill, Department of Psychiatry, Chapel Hill 27599 7160, USA
    J Clin Psychiatry 63:1121-8. 2002
    ..The health belief model views noncompliance as a decision made by the patient, arrived at after weighing the perceived risks and benefits of treatment...
  70. pmc Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia
    Dominique Arion
    Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Biol Psychiatry 62:711-21. 2007
    ..Schizophrenia is characterized by complex gene expression changes. The transcriptome alterations in the prefrontal cortex have been the subject of several recent postmortem studies that yielded both convergent and divergent findings...
  71. ncbi Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment
    Arusha Farahani
    Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
    J Clin Psychiatry 73:486-96. 2012
    ..To perform a meta-analysis of antidepressant-antipsychotic cotreatment versus antidepressant or antipsychotic monotherapy for psychotic depression...
  72. ncbi Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia
    Peter J Weiden
    State University of New York in Brooklyn, USA
    Psychiatr Serv 55:886-91. 2004
    ..The objective of this study was to evaluate the relationship between compliance with an antipsychotic medication regimen and risk of hospitalization in a cohort of California Medicaid patients with schizophrenia...
  73. ncbi Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation
    Anthony C Vernon
    Department of Psychosis Studies, Institute of Psychiatry, King s College London, London, United Kingdom
    Biol Psychiatry 69:936-44. 2011
    ..To examine this, we developed a rodent model that uses clinically relevant doses and serial magnetic resonance imaging (MRI), followed by postmortem histopathological analysis to study the effects of APD on brain structures...
  74. ncbi Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials
    Claudia Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 127:83-92. 2011
    ..Non-adherence is a major problem in the treatment of schizophrenia. Depot antipsychotic drugs are thought to reduce relapse rates by improving adherence, but a systematic review of long-term studies in outpatients is not available...
  75. ncbi From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis
    Shitij Kapur
    Centre for Addiction and Mental Health, Toronto, Canada
    Schizophr Res 79:59-68. 2005
    ..The article discusses the caveats, limitations as well as the clinical implications of the salience framework...
  76. ncbi Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study
    John W Devlin
    Northeastern University School of Pharmacy, Boston, MA, USA
    Crit Care Med 38:419-27. 2010
    ..To compare the efficacy and safety of scheduled quetiapine to placebo for the treatment of delirium in critically ill patients requiring as-needed haloperidol...
  77. ncbi Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis
    Andrea Cipriani
    Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, University of Verona, Italy
    Lancet 378:1306-15. 2011
    ..We did a multiple-treatments meta-analysis, which accounted for both direct and indirect comparisons, to assess the effects of all antimanic drugs...
  78. ncbi Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters
    Kieran J Davey
    Alimentary Pharmabiotic Centre, Laboratory of Neurogastroenterology, University College Cork, Cork, Ireland
    Psychopharmacology (Berl) 221:155-69. 2012
    ..Thus, we investigated the effects of olanzapine on body weight, behaviour, gut microbiota and inflammatory and metabolic markers in both male and female rats...
  79. ncbi Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
    Michael F Green
    Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, USA
    Schizophr Res 72:41-51. 2004
    ..These steps are apt to have important implications for clinical trials of cognition-enhancing agents in schizophrenia...
  80. ncbi A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:673-86. 2009
    ..Asenapine is approved for bipolar disorder and schizophrenia. This was a 3-week, randomized, double-blind, placebo-controlled trial of asenapine for treating acute bipolar mania...
  81. ncbi Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat
    Masafumi Kodama
    Division of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    Biol Psychiatry 56:570-80. 2004
    ..There has been increasing evidence that atypical antipsychotics are effective in the treatment of mood disorders or for augmenting 5-hydroxytryptamine selective reuptake inhibitors for treatment-resistant depression...
  82. ncbi Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis
    Vincenzo De Luca
    University of Toronto, Centre for Addiction and Mental Health, Neurogenetics Section, Toronto, ON, Canada
    Int J Neuropsychopharmacol 10:697-704. 2007
    ..Our meta-analysis provides support for the association of HTR2C in weight gain but indicates that firmly establishing the role of pharmacogenetics in clinical psychiatry requires much larger sample sizes that have been hitherto reported...
  83. ncbi Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA
    Am J Geriatr Psychiatry 14:191-210. 2006
    ..Several clinical trials have not shown efficacy, and there have been concerns about adverse events. The objective of this study was to assess the evidence for efficacy and adverse events of atypicals for people with dementia...
  84. ncbi Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
    Mahesh N Samtani
    Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
    CNS Drugs 25:829-45. 2011
    ..Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic...
  85. pmc Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia
    Yael Piontkewitz
    Department of Psychology, Tel Aviv University, Tel Aviv, Israel
    Schizophr Bull 37:1257-69. 2011
    ..Furthermore, highly selective 5HT(2A) receptor antagonists may be promising targets for psychosis prevention...
  86. ncbi Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn, USA
    Am J Psychiatry 168:957-67. 2011
    ..The study was designed to evaluate the short-term efficacy and safety of lurasidone in the treatment of acute schizophrenia...
  87. ncbi The case for long-acting antipsychotic agents in the post-CATIE era
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0599, USA
    Acta Psychiatr Scand 115:260-7. 2007
    Long-acting antipsychotic agents were developed to promote treatment compliance in patients requiring maintenance treatment for schizophrenia.
  88. ncbi Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals
    Dennis Velakoulis
    Melbourne Neuropsychiatry Centre and Department of Psychiatry, University of Melbourne, Australia
    Arch Gen Psychiatry 63:139-49. 2006
    ..These studies have been limited by small samples and the absence of patients early in the course of illness...
  89. pmc Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis
    V L Albaugh
    Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Mol Psychiatry 16:569-81. 2011
    ..Collectively, these results suggest that olanzapine exerts several metabolic effects that together favor increased accumulation of fuel into adipose tissue, thereby increasing adiposity...
  90. ncbi Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Int Clin Psychopharmacol 25:247-56. 2010
    ..than placebo (>or=5% difference) were headache, vomiting, extremity pain, and injection site pain. Treatment with paliperidone palmitate (100 mg eq.) was efficacious and all doses tested were tolerable...
  91. ncbi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
    ..The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia...
  92. pmc Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis
    Nicolas A Crossley
    Division of Psychological Medicine, Institute of Psychiatry PO 67, De Crespigny Park, London SE58AF
    Br J Psychiatry 196:434-9. 2010
    ..There is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis...
  93. ncbi The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression
    Heinz Grunze
    Newcastle University, RVI, Division of Psychiatry, Institute of Neuroscience, Newcastle upon Tyne, UK
    World J Biol Psychiatry 11:81-109. 2010
    ..Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults...
  94. pmc Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions
    P R Corlett
    Brain Mapping Unit, Department of Psychiatry, University of Cambridge, School of Clinical Medicine, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    Brain 130:2387-400. 2007
    ..Our results support a neurobiological theory of delusion formation that implicates aberrant prediction-error signalling, disrupted attentional allocation and associative learning in the formation of delusional beliefs...
  95. ncbi Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, USA
    Schizophr Res 116:107-17. 2010
    ..We assessed efficacy and tolerability of the injectable atypical antipsychotic paliperidone palmitate in delaying time-to-relapse in adults with schizophrenia...
  96. ncbi A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
    Am J Psychiatry 166:152-63. 2009
    ..The authors conducted a systematic review and meta-analysis of blinded studies comparing second-generation antipsychotics head-to-head...
  97. ncbi Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings
    S Navari
    Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King s College London, UK
    Psychol Med 39:1763-77. 2009
    ..This review addresses two issues: (1) do antipsychotic medications induce changes in total or regional human brain volumes and (2) do such effects depend on antipsychotic type?..
  98. ncbi Intervention in individuals at ultra-high risk for psychosis: a review and future directions
    Patrick D McGorry
    Centre for Youth Mental Health, Orygen Youth Health Research Centre, University of Melbourne, Victoria, Australia
    J Clin Psychiatry 70:1206-12. 2009
    ..This article reviews intervention research in the ultra-high-risk phase of psychotic disorders...
  99. ncbi Adverse effects of antipsychotic medications
    John Muench
    Oregon Health and Sciences University, 3181 SW Sam Jackson Park Blvd, Portland, OR 97213, USA
    Am Fam Physician 81:617-22. 2010
    ..They should be vigilant for the occurrence of adverse effects, be willing to adjust or change medications as needed (or work with psychiatric colleagues to do so), and be prepared to treat any resulting medical sequelae...
  100. ncbi Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    Arch Gen Psychiatry 59:337-45. 2002
    ..While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity...
  101. ncbi Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients
    Ric M Procyshyn
    British Columbia Mental Health and Addictions Research Institute, A3 113, 938 W 28th Ave, Vancouver, British Columbia, Canada, V5Z 4H4
    J Clin Psychiatry 71:566-73. 2010
    ....

Research Grants78

  1. Tyrosine Availability Influences Mesocortico-Limbic Catecholamines
    GEORGE EUGENE JASKIW; Fiscal Year: 2012
    ..Our data will fill in fundamental gaps in our understanding of how brain dopamine systems work. This will help researchers who study these other brain disorders. ..
  2. Genetics and Haloperidol Response
    Robert J Hitzemann; Fiscal Year: 2012
    ....
  3. Mechanisms of Bone Loss from Administration of the Second-Generation Antipsychoti
    KATHERINE JEAN MOTYL; Fiscal Year: 2013
    ..My results will also add to the increasing evidence for a key role of the nervous system in regulating skeletal homeostasis. ..
  4. CHOLINERGIC MECHANISMS OF REM SLEEP GENERATION
    Helen A Baghdoyan; Fiscal Year: 2013
    ..The aims are unified by their ability to provide insights into the neurochemical mechanisms modulating cholinergic neurotransmission in brain regions regulating sleep and wakefulness. ..
  5. ULTRASTRUCTURE OF MESOLIMBIC TRANSMITTER INTERACTIONS
    Virginia M Pickel; Fiscal Year: 2012
    ..abstract_text> ..
  6. Aging and Antipsychotic Efficacy - Epigenetic Mechanisms
    Hongxin Dong; Fiscal Year: 2013
    ..By advancing our understanding of the epigenetic mechanisms of drug efficacy, it will be possible to develop new psychotropic treatment strategies that maximize benefits while minimizing side effects. ..
  7. Metabolic Effects of Antipsychotics in Children
    John W Newcomer; Fiscal Year: 2010
    ..Relevant data are critically needed to assess the risks of antipsychotic therapy in children, to identify targets for additional basic research, and to guide clinical decision-making. ..
  8. The MIND USA Study
    E Wesley Ely; Fiscal Year: 2012
    ..This investigation will determine if either haloperidol or ziprasidone shorten delirium duration, improve survival, affect length of stay in the hospital, or improve long-term brain function and quality of life at 1-year follow-up. ..
  9. Reducing Weight and Diabetes Risk in an Underserved Population
    Carla A Green; Fiscal Year: 2012
    ..These risks are amplified by the antipsychotic agents that are often prescribed to treat these mental conditions...
  10. Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
    Michael R Rickels; Fiscal Year: 2012
    ..Findings from these studies will have important clinical relevance to the treatment of schizophrenia. ..
  11. Heat Waves, Medication Use, and Adverse Health Outcomes Among Older Adults
    SOKO SETOGUCHI-IWATA; Fiscal Year: 2013
    ....
  12. Long-Term Safety and Genetic Risk Factors of Risperdone Treatment in Youth
    Chadi A Calarge; Fiscal Year: 2010
    ....
  13. Negative symptoms of schizophrenia: animal models
    Athina Markou; Fiscal Year: 2013
    ....
  14. High-throughput behavior-based dopaminergic drug discovery in the zebrafish
    David Kokel; Fiscal Year: 2013
    ..Eventually, I hope that this work will lead to novel therapeutic approaches for treating mental illness and other neurological disorders. ..
  15. Keystone Symposia on Cellular and Molecular Basis of Metabolic Disorders Series
    JAMES WAVELL AIKEN; Fiscal Year: 2013
    ..The meeting also discusses new technical advances designed to penetrate the molecular pathogenesis of Type 2 diabetes. ..
  16. Pharmacoepidemiology of Atypical Antipsychotic Drugs
    William V Bobo; Fiscal Year: 2013
    ..antipsychotic drugs. These studies will provide essential data for community practice that cannot be easily or feasibly addressed through randomized controlled trials or conventional post-marketing surveillance. ..
  17. Statewide Intervention to Reduce Early Mortality in Persons with Mental Illness
    Stephen J Bartels; Fiscal Year: 2013
    ..intervention (AD) that will target prescribers using Medicaid pharmacy claims to encourage decreased use of antipsychotic agents with high weight-gain propensity and decreased use of polypharmacy...
  18. Locus Coeruleus-Norepinephrine System Regulation of Prepulse Inhibition
    Vaishali P Bakshi; Fiscal Year: 2010
    ..This proposal will study the neurobiology of the information-processing deficits seen in illnesses like schizophrenia in order to ultimately develop new treatments for these diseases. ..
  19. Genetics of Parkinsonism in a Special Population of Untreated Schizophrenia
    Gabriel Alejandro De Erausquin; Fiscal Year: 2013
    ..Lastly, we anticipate that our research strategy may indicate new waysto study and address the increased vulnerability of schizophrenic patients to nicotine dependence. ..
  20. Effect of Atypical Antipsychotics on Fructose Metabolism and Weight Gain
    CAROLINE PALAVICINO-MAGGIO; Fiscal Year: 2012
    ....
  21. Metabolic Screening: Prioritizing Implementation Strategies for Mental Health
    Elaine H Morrato; Fiscal Year: 2013
    ....
  22. Constructing inhibitory synapses
    Stephen J Moss; Fiscal Year: 2013
    ..This study has the potential to make contributions to the development of novel therapeutics to alleviate schizophrenia in addition to a plethora of other neuropsychiatric disorders in which modified inhibition is of significance. ..
  23. Assessing GABAergic Involvement in Schizophrenia-Like Cognitive Deficits in Rats
    Mark Renato Stefani; Fiscal Year: 2012
    ....
  24. Beta-catenin modulates dopamine dependent signal transduction and behavior.
    JOSHUA CLAIR SNYDER; Fiscal Year: 2013
    ..Completion of this proposal will provide further insight into dopamine dependent signaling and behaviors. Ultimately, this may provide a framework for the development of more efficacious treatments of neurological disease. ..
  25. Development of Novel Agents for CNS-related Diseases
    Seth Y Ablordeppey; Fiscal Year: 2012
    ..Atypical Antipsychotic Agents (AAAs) or Second Generation Antipsychotics (SGAs), typified by clozapine and olanzapine, have replaced ..
  26. Selecting Best Neuroleptic Treatment for Veterans with Schizophrenia
    Erin A Hazlett; Fiscal Year: 2013
    ..Demonstration of the usefulness of caudate and sensorimotor gating measures as biomarkers for predicting treatment response in schizophrenia patients could bring ecologically-valid tools from bench to bedside. ..
  27. Small RNA regulation of BDNF expression in schizophrenia
    Schahram Akbarian; Fiscal Year: 2012
    ....
  28. Structural and Functional Alterations of Interneurons in Models of Schizophrenia
    Istvan Mody; Fiscal Year: 2012
    ..The rational design of GABAergic therapeutics, though, will require a more detailed understanding of how functional imbalances in the multiple facets of GABAA receptor-mediated signaling contribute to schizophrenic symptoms. ..
  29. Akt/GSK-3 Signaling Cascade and the Actions of Dopamine
    Marc G Caron; Fiscal Year: 2013
    ....
  30. Akt/GSK-3 Signaling Cascade and the Actions of Dopamine
    Marc G Caron; Fiscal Year: 2011
    ....
  31. Mechanisms of drug side effects related to obesity and diabetes
    CHRISTOPHER JOHN LYNCH; Fiscal Year: 2013
    ..This will aid in the design of next generation drugs with reduced side effects and may also reveal new therapeutic targets for the treatment of obesity and diabetes. ..
  32. Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children
    GINGER ELLEN NICOL; Fiscal Year: 2013
    ....
  33. Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis
    Tyrone D Cannon; Fiscal Year: 2010
    ..The results of this study will be crucial for the development of cost-effective, evidence-based psychosocial approaches to psychosis prevention and thus will have major implications for public health. ..
  34. In vitro tools for preclinical analysis of cognitive therapies for schizophrenia
    KRISTEN RICHARDSON; Fiscal Year: 2012
    ....
  35. 2/2-D-Cycloserine Augmentation of CBT for Pediatric OCD
    Daniel A Geller; Fiscal Year: 2013
    ..This study will yield clinically important data, which could ultimately improve the treatment of youth with OCD and reduce exposure to potentially harmful medications. ..
  36. 1/2-D-Cycloserine Augmentation of CBT for Pediatric OCD
    Eric A Storch; Fiscal Year: 2013
    ..This study will yield clinically important data, which could ultimately improve the treatment of youth with OCD and reduce exposure to potentially harmful medications. ..
  37. 3/3-Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)
    Christoph U Correll; Fiscal Year: 2012
    ..The results of this project will inform future treatment for children and adolescents with major psychiatric disorders. The results are also likely to lead to treatments that improve their health and longevity. ..
  38. 2/3-Improving Metabolic Parameters of Antipsychotic Child Treatment
    Linmarie Sikich; Fiscal Year: 2012
    ..The results of this project will inform future treatment for children and adolescents with major psychiatric disorders. The results are also likely to lead to treatments that improve their health and longevity. ..
  39. 1/3-Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)
    Mark A Riddle; Fiscal Year: 2012
    ..The results of this project will inform future treatment for children and adolescents with major psychiatric disorders. The results are also likely to lead to treatments that improve their health and longevity. ..
  40. Dopamine action in pancreatic islet function
    David W Piston; Fiscal Year: 2013
    ....
  41. Medications and the Risk of Sudden Cardiac Death
    Wayne A Ray; Fiscal Year: 2013
    ..The resulting data will enable clinicians to make safer drug choices, particularly for patients with high baseline cardiovascular risk. ..
  42. Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
    Drake Morgan; Fiscal Year: 2013
    ..abstract_text> ..
  43. Environmental Factors in Cognition and Neurobiology of Early Onset Schizophrenia
    Konasale M Prasad; Fiscal Year: 2013
    ..The latter may pave the way for future studies on potentially preventive strategies. ..
  44. Muscarinic receptor activators as antipsychotic agents
    Jeffrey P Conn; Fiscal Year: 2013
    ..Studies are proposed to test the hypothesis that these novel molecules have actions that predict efficacy in treatment of schizophrenia. ..
  45. Neurotensin Analogs For Neurocognitive Deficits In Schizophrenia
    Adam Prus; Fiscal Year: 2009
    ....
  46. DAAO Inhibitors for the treatment of Schizophrenia
    Takashi Tsukamoto; Fiscal Year: 2013
    ..Preclinical candidates identified from this project will have the potential to serve as truly novel antipsychotic drugs for schizophrenia patients, particularly those suffering from negative symptoms and cognitive impairments. ..
  47. GABA and Early Intervention of Schizophrenia
    Tsung Ung W Woo; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE The goal of this study is to test the hypothesis that enhancement of inhibitory neural transmission during the early course of schizophrenia may improve cognitive and symptomatic deficits. ..
  48. Role of transcription factors in the action of antipsychotic drugs
    SAMUEL NEWTON SATHYANESAN; Fiscal Year: 2010
    ..Several studies have reported the brain region specific induction of DNA-binding proteins (transcription factors, TF) by these drugs. The functional activity of these transcription factors using microarray chips. ..
  49. Effectiveness of Feeding Tubes Among Person with Advanced Cognitive Impairment
    Joan M Teno; Fiscal Year: 2010
    ..The proposed research will provide authoritative evidence of the effectiveness of feeding tubes and identify modifiable hospital characteristics and state policies that account for the observed striking variation in feeding tube use. ..
  50. Endogenous Kynurenic Acid Modulates Prefrontal ACh Levels and Cognitive Behavior
    Robert Schwarcz; Fiscal Year: 2013
    ..We will use these findings to generate an experimental platform for testing the therapeutic efficacy of KYNA-based treatments in alleviating the cognitive deficits seen in SZ. ..
  51. Molecular Determinants for the Action of Psychostimulants
    Jonathan A Javitch; Fiscal Year: 2013
    ....
  52. Prodrugs of NAAG Peptidase Inhibitors for the Treatment of Schizophrenia
    Jia Zhou; Fiscal Year: 2009
    ....
  53. GLUTAMATERGIC DYSFUNCTION AND SCHIZOPHRENIA
    Joseph T Coyle; Fiscal Year: 2010
    ..Biostatistical Core: Lange will provide statistical support for Center investigators. Administrative Core: Coyle will provide scientific oversight and budgetary administration to insure that the goals are achieved. ..
  54. Design of New Therapeutic Agents to Treat Schizophrenia
    James M Cook; Fiscal Year: 2013
    ..The proposed work is significant because it represents the first step in a continuum of research to develop the first therapies for impaired cognitive function and negative symptoms of schizophrenia patients. ..
  55. Citalopram Treatment for Agitation in Alzheimer Dementia
    Constantine G Lyketsos; Fiscal Year: 2012
    ....
  56. Optimizing Lead 5-HT2c Ligands for Use in the Treatment of Schizophrenia
    William C Wetsel; Fiscal Year: 2013
    ....
  57. A Potential State and Relapse Predictive Marker in Schizophrenia
    BRIAN JAMES MILLER; Fiscal Year: 2013
    ....
  58. Understanding the Impact of Antipsychotic Drugs on Recovery After TBI
    Anthony E Kline; Fiscal Year: 2013
    ..Furthermore, these studies will have an immediate impact on clinical care by providing clinicians critical information about the effects of APDs after TBI. ..
  59. NALTREXONE FOR ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
    Cenk Tek; Fiscal Year: 2013
    ....
  60. AMY-1 receptors: Novel targets for antipsychotic development
    Brian A Baldo; Fiscal Year: 2012
    ..In the course of this last study, we will also determine whether amylin-related genes themselves are developmentally regulated. ..
  61. Determining the role of dopamine D2L versus D2S receptors in vivo
    Emiliana Borrelli; Fiscal Year: 2013
    ..Thus expanding our scientific knowledge of dopamine-mediated responses and providing crucial information for pharmacological designing of D2-targeted drugs. ..
  62. Relating GPCRs by biased ligands for enhanced therapeutic efficacy
    MICHAEL JAMES KEISER; Fiscal Year: 2013
    ..Whereas these goals are admittedly ambitious, preliminary results suggest that they are feasible. ..
  63. Anxiolytic Property of Atypical Antipsychotics
    Ming Li; Fiscal Year: 2009
    ..Such findings are expected to have a positive impact on the development and evaluation of psychotropic drugs and on the treatment of patients with schizophrenia. ..
  64. MOTOR EFFECTS OF ATYPICAL ANTIPSYCHOTICS
    John Salamone; Fiscal Year: 2003
    ..Taken together, the results of these experiments will help to identify the pharmacological characteristics and brain circuits that underlie the motor effects of clozapine. ..
  65. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2007
    ..This information will help to provide a more rational basis for making treatment decisions concerning children and adolescents who may benefit from treatment with an antipsychotic. [unreadable] [unreadable]..
  66. XEROSTOMIA-INDUCING MECHANISMS OF PSYCHOTROPIC DRUGS
    JIA HUEY YU; Fiscal Year: 1993
    ..It would also provide information regarding the beneficial effect of a pharmacologic agent, Sialor, in antagonizing drug-induced changes in salivary gland function...
  67. MECHANISMS OF CARDIOTOXICITY OF ANTIPSYCHOTIC DRUGS
    David Flockhart; Fiscal Year: 2001
    ..3) To determine if antipsychotic agents that are found to be potentially cardiotoxic in vitro have clinical electrocardiac effects at the doses ..
  68. Evaluating Psychotropic Oversight on the Safety of Children in Foster Care
    THOMAS I MACKIE; Fiscal Year: 2012
    ....
  69. Heterogeneity and Econometric Net Cost Estimates of Schizophrenia Drug Treatments
    David Salkever; Fiscal Year: 2009
    ..Review note: This application is submitted as an R03 small grant in response to PA-06-180;the content is within the scope of "Research in Mental Health Economics" (NIMH PA-07-213). ..
  70. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. [unreadable] [unreadable] [unreadable] [unreadable]..
  71. BIOSYNTHESIS OF OLEAMIDE AND OTHER FATTY ACID AMIDES
    DAVID MERKLER; Fiscal Year: 1999
    ..Accomplishing this goal will establish the role of a-AE and oleoylglycine in the biosynthesis oleamide in the mammalian cells of neural origin. ..
  72. Procognitive and Antipsychotic Actions of JWS-USC-75-IX
    Alvin Terry; Fiscal Year: 2009
    ....
  73. Accelerating Utilization of CE Findings in Medicaid Mental Health
    Stephen Crystal; Fiscal Year: 2010
    ..Results will be evaluated and disseminated nationally;the potential impact is extremely large given the large number of beneficiaries affected. ..
  74. Treatment of Psychotic Disorders in Youth
    Linmarie Sikich; Fiscal Year: 2006
    ....
  75. Serotonin Glutamate Interactions in Prefrontal Cortex
    Gerard Marek; Fiscal Year: 2001
    ..As such, this multi-disciplinarian study may provide new strategies to develop novel antidepressant treatments that would be more efficacious than simply blocking 5-HT2A receptors. ..
  76. Acute Impact of Antipsychotics on Insulin Sensitivity: A Novel Human Model
    Jonathan Meyer; Fiscal Year: 2009
    ..The purpose of this project is to study a novel model for exploring the acute metabolic impact of antipsychotics that minimizes the subject risks seen in prior human studies, and is more easily replicated. ..
  77. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan I Green; Fiscal Year: 2010
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  78. Antipsychotics and Mortality in Older Patients
    HELEN KALES; Fiscal Year: 2009
    ..our prior work to examine further critical questions including: 1) comparing mortality risks for individual antipsychotic agents in older patients both with and without dementia diagnoses in the 12 months following a new antipsychotic ..